| Name | Title | Contact Details |
|---|---|---|
Amy Hiddessen |
Vice President, Product Development | Profile |
Elizabeth Holland |
Vice President Human Resources | Profile |
Kevin Ness |
Chief Executive Officer | Profile |
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics.
Genomenon is an AI-driven genomics company whose mission is to save and improve lives by making genomic information actionable for patients with rare genetic diseases and cancer.
Akonni Biosystems is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CTMG is a Greenville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.